These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3355613)

  • 1. A little more information about aggravation of probucol-induced HDL-reduction by clofibrate.
    Yokoyama S; Yamamoto A; Kurasawa T
    Atherosclerosis; 1988 Mar; 70(1-2):179-81. PubMed ID: 3355613
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of probucol on serum lipoprotein levels in normal and dyslipoproteinemic mice.
    Tomikawa M; Nakayasu T; Tawara K; Abiko Y
    Atherosclerosis; 1981 Oct; 40(2):101-13. PubMed ID: 6946776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-density lipoprotein and apolipoprotein A-I deficiency induced by combination therapy with probucol and bezafibrate.
    Saku K; Zhang B; Jimi S; Bai H; Hirata K; Sasaki N; Liu R; Arakawa K
    Eur J Clin Pharmacol; 1995; 48(3-4):209-15. PubMed ID: 7589043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of probucol on xanthomata regression in familial hypercholesterolemia.
    Yamamoto A; Matsuzawa Y; Yokoyama S; Funahashi T; Yamamura T; Kishino B
    Am J Cardiol; 1986 Jun; 57(16):29H-35H. PubMed ID: 3728307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of probucol treatment on lipoprotein cholesterol and drug levels in blood and lipoproteins in familial hypercholesterolemia.
    Fellin R; Gasparotto A; Valerio G; Baiocchi MR; Padrini R; Lamon S; Vitale E; Baggio G; Crepaldi G
    Atherosclerosis; 1986 Jan; 59(1):47-56. PubMed ID: 3081013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe hypoalphalipoproteinemia induced by a combination of probucol and clofibrate.
    Davignon J; Nestruck AC; Alaupovic P; Bouthillier D
    Adv Exp Med Biol; 1986; 201():111-25. PubMed ID: 3541510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects.
    Heller F; Harvengt C
    Eur J Clin Pharmacol; 1983; 25(1):57-63. PubMed ID: 6617725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probucol: effects on the metabolism of low density and high density lipoproteins in moderate hypercholesterolaemia.
    Magill P; Whiting C; Hammett F; Glick I; Miller NE; Lewis B
    Artery; 1982; 10(2):88-94. PubMed ID: 7092581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of probucol on plasma lipoproteins in polygenic and familial hypercholesterolaemia.
    Cortese C; Marenah CB; Miller NE; Lewis B
    Atherosclerosis; 1982 Sep; 44(3):319-25. PubMed ID: 7150396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacology of probucol. I].
    Donatelli L
    Clin Ter; 1984 Mar; 108(5):367-88. PubMed ID: 6232074
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of probucol on lipoprotein protein kinetics.
    Nestel PJ
    Artery; 1982; 10(2):95-8. PubMed ID: 7092582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma carnitine and lipid-lowering drugs.
    Nestruck AC; Pande SV; Davignon J
    Atherosclerosis; 1985 Jun; 55(3):353-6. PubMed ID: 4015753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lowered HDL cholesterol and incidence of ischaemic heart disease.
    Miettinen TA; Huttunen JK; Strandberg T; Naukkarinen V; Mattila S; Kumlin T
    Lancet; 1981 Aug; 2(8244):478. PubMed ID: 6115240
    [No Abstract]   [Full Text] [Related]  

  • 14. Is it harmful to lower HDL levels?
    Henahan J
    JAMA; 1981 Nov; 246(20):2311, 2315. PubMed ID: 7299948
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term use of probucol in the multifactorial primary prevention of vascular disease.
    Miettinen TA; Huttunen JK; Naukkarinen V; Strandberg T; Vanhanen H
    Am J Cardiol; 1986 Jun; 57(16):49H-54H. PubMed ID: 2873740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modifications in the chemical composition and thermometric behavior of LDL and HDL by probucol in type IIa hyperlipoproteinemia.
    Dachet C; Motta C; Neufcour D; Jacotot B
    Adv Exp Med Biol; 1988; 243():179-84. PubMed ID: 3223415
    [No Abstract]   [Full Text] [Related]  

  • 17. The additive effects of clofibrate and probucol (DH-581) on rat serum cholesterol.
    Duncan CH; Best MM
    Atherosclerosis; 1973; 17(2):161-6. PubMed ID: 4709117
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of probucol and cholestyramine combination therapy in severe familial hypercholesterolaemia.
    Jackson JM; Lee HA
    Atherosclerosis; 1984; 51(2-3):189-97. PubMed ID: 6743378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of clofibrate, bile-sequestering agents and probucol on high-density lipoprotein levels.
    Glueck C
    Am J Cardiol; 1983 Aug; 52(4):28B-30B. PubMed ID: 6577781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effects of probucol in man (author's transl)].
    Leutenegger M
    Nouv Presse Med; 1980 Oct; 9(40):2985-9. PubMed ID: 7443436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.